|
|
|
|
Profound Medical Corp (PROF) |
|
Price: $7.0500
$-0.17 
-2.355%
|
| Day's High:
| $7.3
| Week Perf:
| -4.08 %
|
| Day's Low: |
$ 7.00 |
30 Day Perf: |
-2.76 % |
| Volume (M): |
63 |
52 Wk High: |
$ 11.42 |
| Volume (M$): |
$ 441 |
52 Wk Avg: |
$8.21 |
| Open: |
$7.18 |
52 Wk Low: |
$6.78 |
|
|
| Market Capitalization (Millions $) |
149 |
| Shares
Outstanding (Millions) |
21 |
| Employees |
174 |
| Revenues (TTM) (Millions $) |
7 |
| Net Income (TTM) (Millions $) |
29 |
| Cash Flow (TTM) (Millions $) |
47 |
| Capital Exp. (TTM) (Millions $) |
0 |
Profound Medical Corp
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Dividend
Published Wed, Jan 8 2025 12:31 PM UTC
Profound Medical Reports Strong Revenue Growth for Q4 and Full Year 2024 Amidst Ongoing Innovations in OncologyProfound Medical, a leading entity in the field of medical technology focusing on the treatment of prostate cancer, has recently released preliminary unaudited revenues for the fourth quarter and the full year of 2024. This announcement highlights a remarkable year ...
|
| Shares
Published Tue, Dec 10 2024 2:55 PM UTC
Profound Medical Secures $40.25 Million: A Strategic Move in Oncology InnovationIn a significant boost to its financial standing, Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) has announced the successful closing of its underwritten public offering, raising a total of US$40.25 million through the sale of common shares. The move not only enhances the company s liquidity bu...
|
| Shares
Published Thu, Dec 5 2024 9:48 PM UTC
Profound Medical Corp. Unveils US$20 Million Public Offering of Common Shares: Key Details and Insights on Funding StrategyIn a significant move to bolster its financial standing and drive future growth, Profound Medical Corp. (TSX:PRN; NASDAQ:PROF), a company at the forefront of healthcare innovation, has announced the pricing of its underwritten public offering of common s...
|
| Product Service News
Published Tue, Nov 26 2024 12:45 PM UTC
In an era where innovation is paramount, Profound Medical continues to assert its presence in the medical technology sector with significant advancements and a focus on clinical efficacy. The company is gearing up to unveil its next TULSA-AI module, the UA Alignment Assistant, at the upcoming Radiological Society of North America (RSNA) and Society of Urologic Oncology (SUO)...
|
| Product Service News
Published Mon, Nov 4 2024 11:55 AM UTC
Profound Medical s TULSA Reimbursement Elevated to Urology APC Level 7 Under CMS OPPS Final Rule for CY2025 In a significant development for the treatment of prostate diseases, Profound Medical Inc. recently announced that their innovative TULSA procedure has been granted a reimbursement increase to Urology Ambulatory Payment Classification (APC) Level 7 under the Centers fo...
|
| Per Share |
Current |
| Earnings (TTM) |
1.35 $ |
| Revenues (TTM) |
0.34 $
|
| Cash Flow (TTM) |
2.2 $ |
| Cash |
1.24 $
|
| Book Value |
1.47 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
1.35 $
|
| Revenues (TTM) |
0.34 $ |
| Cash Flow (TTM) |
2.2 $ |
| Cash |
1.24 $
|
| Book Value |
1.47 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
On January 3 2024 the Profound Medical provided following guidance
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) announced its preliminary unaudited revenues for the fourth quarter and full year of 2023. As a leading medical device company, Profound specializes in the development and marketing of customizable, incision-free therapies for the ablation of diseased tissue. The company also provided an update on the commercialization progress of TULSA-PRO in the United States.
Due to the significant time gap between planned investment community meetings and the reporting of final 2023 results in March 2024, Profound chose to release this information. This will coincide with various investor events, including the 42nd Annual J.P. Morgan Healthcare Conference in San Fra...
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
